Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19306722 | METHOD OF RAPID EXTRACTION OF DNA FROM SALIVA AND QPCR AMPLIFICATION OF GROUP A STREPTOCOCCUS DNA | August 2025 | February 2026 | Allow | 6 | 1 | 0 | No | No |
| 19212398 | CHROMATIN PROFILING COMPOSITIONS AND METHODS | May 2025 | November 2025 | Allow | 6 | 1 | 0 | No | No |
| 19172703 | Nucleic Acid Reporter Molecules for Massively Parallel DNA Sequencing | April 2025 | October 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18559322 | SPATIOTEMPORALLY RESOLVED TRANSCRIPTOMICS AT SUBCELLULAR RESOLUTION | November 2023 | February 2026 | Allow | 27 | 0 | 0 | No | No |
| 18296699 | FOOD CERTIFICATION SYSTEM | April 2023 | September 2025 | Allow | 30 | 0 | 0 | No | No |
| 18129274 | METHODS AND COMPOSITIONS RELATING TO DETECTION OF RECOMBINATION AND REARRANGEMENT EVENTS | March 2023 | February 2026 | Allow | 34 | 1 | 0 | No | No |
| 18188927 | Multiplex Isotype-Specific Antibody Detection | March 2023 | October 2025 | Allow | 31 | 0 | 0 | No | No |
| 18166986 | METHODS FOR ANALYZING NUCLEIC ACIDS | February 2023 | January 2026 | Allow | 36 | 1 | 0 | Yes | No |
| 18097990 | METHODS AND COMPOSITIONS FOR IMPROVED PROBE SPECIFICITY | January 2023 | March 2026 | Allow | 38 | 1 | 0 | No | No |
| 18016290 | METHODS FOR THE DETECTION OF A NUCLEIC ACID | January 2023 | January 2026 | Allow | 36 | 1 | 0 | No | No |
| 18003456 | PROTECTION METHOD, PROTECTION SEQUENCE, COMPOSITION AND KIT FOR PREVENTING RNA DEGREADATION, AND USE THEREOF | December 2022 | January 2026 | Allow | 37 | 1 | 0 | No | No |
| 18047063 | DIRECT RNA NANOPORE SEQUENCING WITH HELP OF A STEM-LOOP REVERSE POLYNUCLEOTIDE | October 2022 | July 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17914815 | Compositions and Methods for Nucleic Acid Quality Determination | September 2022 | January 2026 | Allow | 40 | 1 | 1 | No | No |
| 17952414 | POLYNUCLEOTIDE SEQUENCING | September 2022 | August 2025 | Allow | 34 | 0 | 1 | Yes | No |
| 17913352 | DNA REPAIR SITE DETECTION FOR PERSONAL GENOMICS, EPIGENOMICS, AND GENE THERAPY | September 2022 | December 2025 | Allow | 39 | 1 | 0 | No | No |
| 17941758 | Automated Cell Sorting Stage and Methods For Using Same | September 2022 | September 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17898112 | METHODS AND SYSTEMS FOR DETECTING TISSUE CONDITIONS | August 2022 | March 2026 | Allow | 42 | 1 | 0 | Yes | No |
| 17820856 | METHODS AND COMPOSITIONS RELATING TO COVALENTLY CLOSED NUCLEIC ACIDS | August 2022 | October 2025 | Allow | 38 | 1 | 0 | No | No |
| 17820289 | COMPOSITIONS AND METHODS FOR DETECTING GROUP B STREPTOCOCCUS NUCLEIC ACID | August 2022 | March 2026 | Allow | 43 | 1 | 1 | No | No |
| 17760195 | Nucleic Acid Detection Kit For Novel Coronavirus 2019-nCoV | August 2022 | September 2025 | Allow | 38 | 1 | 0 | No | No |
| 17817516 | IN SITU READOUT OF DNA BARCODES | August 2022 | September 2025 | Allow | 37 | 1 | 1 | No | No |
| 17867393 | DISEASE DIAGNOSTIC SYSTEM AND METHOD | July 2022 | October 2025 | Allow | 39 | 1 | 0 | No | No |
| 17793159 | METHODS AND COMPOSITIONS FOR TREATING MELANOMA | July 2022 | February 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17758511 | IMAGE DIFFERENTIATED MULTIPLEX ASSAYS FOR DETECTION OF DNA MUTATIONS IN LUNG CANCER | July 2022 | August 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17790490 | A fluorescent quantitative PCR technology-based method for distinguishing human DNA | June 2022 | January 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17839014 | LAMP PRIMER SET AND METHOD FOR AMPLIFYING NUCLEIC ACIDS USING THE SAME | June 2022 | December 2025 | Allow | 42 | 1 | 1 | No | No |
| 17715894 | METHODS FOR ASYMMETRIC SEMI-NESTED ISOTHERMAL NUCLEOTIDE AMPLIFICATION | April 2022 | January 2026 | Allow | 45 | 2 | 0 | Yes | No |
| 17642887 | Adapter Molecule, Biomolecule-Adapter Molecule Complex in Which Said Adapter Molecule and Biomolecule Are Bound, Biomolecule Analysis Apparatus, and Biomolecule Analysis Method | March 2022 | March 2026 | Allow | 48 | 2 | 1 | Yes | No |
| 17667334 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION | February 2022 | November 2025 | Allow | 45 | 1 | 0 | No | No |
| 17521350 | STABILIZATION OF NUCLEIC ACIDS IN URINE | November 2021 | November 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17471932 | METHODS AND DEVICES FOR AMPLIFICATION OF NUCLEIC ACID | September 2021 | February 2026 | Abandon | 53 | 1 | 0 | No | No |
| 17378267 | DETECTING COLORECTAL NEOPLASM | July 2021 | November 2023 | Allow | 28 | 1 | 0 | No | No |
| 17282424 | CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS FOR HEMORRHAGIC FEVER DETECTION | April 2021 | July 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17279534 | TUMOR HLA MUTATION VERSUS MATCHED NORMAL HLA | March 2021 | September 2025 | Allow | 54 | 3 | 1 | Yes | No |
| 17174799 | OLIGONUCLEOTIDE PROBE FOR THE SPECIFIC DETECTION OF MICROORGANISMS, CORRESPONDING METHOD AND USE | February 2021 | May 2025 | Allow | 51 | 4 | 1 | Yes | No |
| 17048311 | Positionally Assisted Negative particle Rejection (PANR) to sort and enrich target cells of interest | October 2020 | February 2024 | Allow | 40 | 1 | 0 | No | No |
| 16975678 | MOLECULAR TARGETS FOR FETAL NUCLEIC ACID ANALYSIS | August 2020 | May 2025 | Abandon | 57 | 3 | 0 | No | No |
| 16032183 | APPARATUS AND METHODS FOR INTEGRATED SAMPLE PREPARATION, REACTION AND DETECTION | July 2018 | January 2020 | Allow | 18 | 1 | 0 | No | No |
| 15589392 | BACTERIAL PATHOGEN IDENTIFICATION BY HIGH RESOLUTION MELTING ANALYSIS | May 2017 | November 2019 | Allow | 30 | 2 | 1 | Yes | No |
| 15326604 | ISOTHERMAL METHODS FOR AMPLIFYING NUCLEIC ACID SAMPLES | January 2017 | June 2019 | Allow | 29 | 1 | 0 | No | No |
| 15293387 | METHODS FOR MULTIPLEXING AMPLIFICATION REACTIONS | October 2016 | June 2018 | Allow | 20 | 1 | 0 | Yes | No |
| 15252555 | METHODS AND REAGENTS THAT SPECIFICALLY DETECT, DISTINGUISH AND QUANTIFY IFN-LAMBDA2 mRNA FROM IFN-LAMBDA3 mRNA IN HUMANS | August 2016 | July 2018 | Allow | 23 | 0 | 0 | No | No |
| 15250259 | RAPID WHOLE GENOME AMPLIFICATION | August 2016 | October 2017 | Allow | 14 | 1 | 0 | No | No |
| 15235959 | RAPID SOLID PHASE EXTRACTION DEVICE AND METHODS | August 2016 | August 2019 | Allow | 36 | 1 | 1 | Yes | No |
| 15102685 | NUCLEIC ACID DETECTION AND QUANTIFICATION | June 2016 | August 2019 | Allow | 38 | 2 | 1 | No | No |
| 15156352 | METHODS OF DIAGNOSING BIPOLAR DISORDERS AND SCREENING FOR THERAPEUTIC COMPOUNDS | May 2016 | April 2019 | Allow | 34 | 2 | 1 | No | No |
| 15085456 | METHODS AND COMPOSITIONS FOR REPAIR OF DNA ENDS BY MULTIPLE ENZYMATIC ACTIVITIES | March 2016 | March 2019 | Allow | 36 | 1 | 1 | No | No |
| 14851837 | DETECTION OF DNA SEQUENCES AS RISK FACTORS FOR HIV INFECTION | September 2015 | October 2018 | Allow | 37 | 2 | 1 | Yes | No |
| 14774648 | Massively Multiplexed RNA Sequencing | September 2015 | November 2019 | Allow | 50 | 4 | 1 | Yes | No |
| 14841015 | METHODS AND MATERIALS FOR DETECTING CONTAMINATED FOOD PRODUCTS | August 2015 | March 2016 | Allow | 6 | 1 | 0 | No | No |
| 14832248 | THERMAL CYCLER AND THERMAL CYCLE METHOD | August 2015 | June 2016 | Allow | 10 | 1 | 0 | No | No |
| 14810388 | METHODS FOR DETECTION AND QUANTIFICATION OF NUCLEIC ACID OR PROTEIN TARGETS IN A SAMPLE | July 2015 | February 2017 | Allow | 18 | 1 | 0 | No | No |
| 14746437 | MULTIPLEX QUANTITATIVE PCR | June 2015 | December 2017 | Allow | 29 | 1 | 1 | Yes | No |
| 14746272 | COMPOSITION AND METHOD FOR IN-SYSTEM PRIMING MICROFLUIDIC DEVICES | June 2015 | January 2017 | Allow | 19 | 1 | 0 | No | No |
| 14648678 | PRIMER MIDDLE SEQUENCE INTERFERENCE PCR TECHNOLOGY | May 2015 | March 2018 | Allow | 34 | 1 | 1 | Yes | No |
| 14697036 | SYSTEMS AND METHODS FOR MONITORING THE AMPLIFICATION OF DNA | April 2015 | May 2017 | Allow | 25 | 1 | 1 | Yes | No |
| 14589864 | METHODS FOR MULTIPLEXING AMPLIFICATION REACTIONS | January 2015 | July 2015 | Allow | 6 | 1 | 0 | No | No |
| 14498827 | COMPOSITIONS AND METHODS FOR REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR) | September 2014 | September 2017 | Allow | 35 | 3 | 0 | No | No |
| 14372692 | METHODS TO MUTATE CIRCULAR DEOXYRIBONUCLEOTIDES | July 2014 | August 2016 | Allow | 25 | 1 | 1 | Yes | No |
| 14331886 | METHOD AND APPARATUS FOR APPLYING CONTINUOUS FLOW AND UNIFORM TEMPERATURE TO GENERATE THERMAL MELTING CURVES IN A MICROFLUIDIC DEVICE | July 2014 | October 2016 | Allow | 27 | 2 | 0 | Yes | No |
| 14330707 | Phased Genome Sequencing | July 2014 | August 2015 | Allow | 13 | 2 | 0 | Yes | No |
| 14172295 | METHOD FOR DETECTING A TARGET PARTICLE | February 2014 | February 2016 | Allow | 24 | 2 | 0 | No | No |
| 14090167 | METHODS AND MATERIALS FOR DETECTING CONTAMINATED FOOD PRODUCTS | November 2013 | February 2015 | Allow | 15 | 1 | 0 | No | No |
| 14017764 | HUMAN EXHALED AEROSOL DROPLET BIOMARKER SYSTEM AND METHOD | September 2013 | November 2016 | Allow | 39 | 2 | 1 | No | No |
| 13960121 | DETECTION OF NUCLEIC ACIDS AND PROTEINS | August 2013 | February 2015 | Allow | 19 | 2 | 0 | Yes | No |
| 13977411 | OLIGONUCLEOTIDE PROBE FOR THE DETECTION OF ADENOVIRUS | July 2013 | July 2016 | Allow | 37 | 2 | 1 | Yes | No |
| 13899284 | Ribosomal Polynucleotides and Related Expression Systems | May 2013 | January 2016 | Allow | 32 | 1 | 1 | Yes | No |
| 13868666 | DETECTION OF NUCLEIC ACIDS AND PROTEINS | April 2013 | May 2014 | Allow | 13 | 1 | 0 | No | No |
| 13880224 | THERMAL CYCLER AND THERMAL CYCLE METHOD | April 2013 | May 2015 | Allow | 25 | 1 | 0 | No | No |
| 13771700 | CHIMERIC DNA IDENTIFIER | February 2013 | August 2016 | Allow | 42 | 4 | 1 | No | No |
| 13768794 | DETECTION OF HPV | February 2013 | February 2014 | Allow | 12 | 1 | 0 | No | No |
| 13764754 | COMPOSITIONS AND METHODS FOR REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR) | February 2013 | January 2014 | Allow | 12 | 4 | 2 | No | No |
| 13752003 | DETECTION OF DNA SEQUENCES AS RISK FACTORS FOR HIV INFECTION | January 2013 | May 2015 | Allow | 28 | 2 | 1 | Yes | No |
| 13682344 | SYSTEM AND METHOD FOR RAPID DETECTION AND IDENTIFICATION OF NUCLEIC ACID LABELED TAGS | November 2012 | August 2015 | Allow | 33 | 1 | 1 | Yes | No |
| 13681574 | DUAL OLIGONUCLEOTIDE METHOD OF NUCLEIC ACID DETECTION | November 2012 | September 2013 | Allow | 10 | 0 | 1 | Yes | No |
| 13520383 | Assembly of High Fidelity Polynucleotides | October 2012 | October 2015 | Allow | 40 | 3 | 0 | No | No |
| 13619436 | METHODS FOR MULTIPLEXING AMPLIFICATION REACTIONS | September 2012 | March 2014 | Allow | 18 | 2 | 0 | No | No |
| 13505598 | SEQUENCE-SPECIFIC METHODS FOR HOMOGENEOUS, REAL-TIME DETECTION OF LAMP PRODUCTS | July 2012 | December 2015 | Allow | 43 | 2 | 1 | Yes | No |
| 13505872 | REACTIVITY-DEPENDENT AND INTERACTION-DEPENDENT PCR | July 2012 | June 2015 | Allow | 37 | 1 | 1 | No | No |
| 13488748 | Method of Manufacturing Nanoparticle Chain | June 2012 | August 2014 | Allow | 27 | 1 | 0 | No | No |
| 13489209 | DETECTION OF NUCLEIC ACIDS AND PROTEINS | June 2012 | May 2014 | Allow | 24 | 2 | 0 | No | No |
| 13472209 | PRIMERS FOR ANALYZING METHYLATED SEQUENCES AND METHODS OF USE THEREOF | May 2012 | December 2012 | Allow | 7 | 1 | 0 | Yes | No |
| 13384712 | OLIGONUCLEOTIDES FOR DETECTING CHICKEN ASTROVIRUS | February 2012 | August 2013 | Allow | 19 | 1 | 0 | No | No |
| 13340572 | SAMPLE ANALYSIS METHOD AND ASSAY KIT USED THEREIN | December 2011 | October 2013 | Allow | 22 | 1 | 2 | Yes | No |
| 13339633 | RAPID WHOLE GENOME AMPLIFICATION | December 2011 | April 2016 | Allow | 52 | 5 | 0 | Yes | No |
| 13379499 | DNA-BASED METHODS FOR CLONE-SPECIFIC IDENTIFICATION OF STAPHYLOCOCCUS AUREUS | December 2011 | November 2015 | Allow | 47 | 4 | 0 | No | No |
| 13299126 | HIGH SPEED, HIGH FIDELITY, HIGH SENSITIVITY NUCLEIC ACID DETECTION | November 2011 | April 2013 | Allow | 16 | 2 | 0 | Yes | No |
| 13297062 | Phased Genome Sequencing | November 2011 | March 2014 | Allow | 28 | 3 | 0 | Yes | No |
| 13296557 | METHOD FOR DETERMINING PREDISPOSITION TO PULMONARY INFECTION | November 2011 | May 2015 | Allow | 42 | 4 | 1 | Yes | No |
| 12305742 | Method for the Detection and Diagnosis of Cancer Involving Primers and Probes for the Specific Detection of the MAGE-A3-Marker | October 2011 | September 2014 | Allow | 60 | 2 | 0 | No | No |
| 13221948 | COMPOSITION AND METHOD FOR IN-SYSTEM PRIMING MICROFLUIDIC DEVICES | August 2011 | March 2015 | Allow | 42 | 1 | 1 | Yes | No |
| 13199380 | Methods and compositions related thereto for detecting and identifying distinct species of nucleic acids from causative agents | August 2011 | September 2014 | Allow | 36 | 4 | 0 | No | Yes |
| 13214547 | NUCLEIC ACID ISOTHERMAL AMPLIFICATION METHOD | August 2011 | September 2013 | Allow | 25 | 2 | 0 | No | No |
| 13195116 | PHYSIOGENOMIC METHOD FOR PREDICTING DIABETES AND METABOLIC SYNDROMES INDUCED BY PSYCHOTROPIC DRUGS | August 2011 | December 2012 | Allow | 16 | 1 | 1 | No | No |
| 13190317 | PRIMERS FOR NUCLEIC ACID AMPLIFICATION IN DETECTING BETA-ACTIN AND TEST METHOD USING THESE PRIMERS | July 2011 | February 2012 | Allow | 6 | 0 | 0 | Yes | No |
| 13135022 | COMPOSITIONS AND METHODS FOR DETECTING CRYPTOCOCCUS NEOFORMANS | June 2011 | October 2012 | Allow | 16 | 1 | 0 | No | No |
| 13123524 | MICROFLUIDIC APPARATUS AND METHOD FOR DNA EXTRACTION, AMPLIFICATION AND ANALYSIS | June 2011 | March 2015 | Allow | 48 | 3 | 1 | Yes | No |
| 13161074 | DETECTION OF NUCLEIC ACIDS AND PROTEINS | June 2011 | February 2013 | Allow | 20 | 0 | 0 | Yes | No |
| 13098613 | GEL HAVING BIOSUBSTANCE FIXED THERETO AND MICROARRAY UTILIZING THE GEL | May 2011 | April 2014 | Allow | 35 | 4 | 0 | Yes | Yes |
| 13018553 | DETECTION OF NUCLEIC ACIDS AND PROTEINS | February 2011 | March 2013 | Allow | 25 | 2 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WILDER, CYNTHIA B.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner WILDER, CYNTHIA B works in Art Unit 1681 and has examined 228 patent applications in our dataset. With an allowance rate of 97.8%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner WILDER, CYNTHIA B's allowance rate of 97.8% places them in the 89% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by WILDER, CYNTHIA B receive 2.39 office actions before reaching final disposition. This places the examiner in the 69% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by WILDER, CYNTHIA B is 36 months. This places the examiner in the 35% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +1.3% benefit to allowance rate for applications examined by WILDER, CYNTHIA B. This interview benefit is in the 20% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 29.5% of applications are subsequently allowed. This success rate is in the 56% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 44.4% of cases where such amendments are filed. This entry rate is in the 68% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 90.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 64.8% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 22.4% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.6% of allowed cases (in the 76% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.